← Leaderboards
Richard D Semba
Johns Hopkins University
$20,161,870
Attributed
$20,161,870
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$20,161,870 · 16
By mechanism
R01$18,911,442 · 10
R56$601,942 · 2
R21$482,794 · 2
R03$163,500 · 1
M01$2,192 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Se-Jin Lee$17,681,857
- Marsha W Wills-Karp$29,249,566
- Ruth R Faden$485,892
- Jonathan M. Samet$20,576,555
- John J Strouse$919,751
Others in their field
Top investigators on “Elderly”
- Charles A Coltman · Southwest Oncology Group$158,376,564
- Richard L Schilsky · University Of Chicago$122,071,723
- Michael W Weiner · Northern California Institute Res &Educ$99,760,701
- Monica M Bertagnolli · Strang Cancer Prevention Center$99,246,201
- Richard Mayeux · Columbia University Health Sciences$83,247,500
- Peter Gordon Gillespie · Oregon Health And Science University$80,983,248
Research focus
ElderlyAgingInsightPathogenesisPlasmaAdultPathway InteractionsBaseSarcopeniaDisabilityInvestigationHuman SubjectNutrition Related TagInflammationClinical TrialsDietary SupplementsMortality Vital StatisticsPlayReceptorProteinsSerumWomanParticipantAids Therapy
Grant awards (60)
Systemic rejuvenating factors and human aging phenotypes.$352,063
R01 · FY2022 · AG · contact PI
Systemic rejuvenating factors and human aging phenotypes.$352,063
R01 · FY2021 · AG · contact PI
Lysophosphatidylcholines and Cognition (L-COG) Study$122,813
R21 · FY2021 · HL · contact PI
Systemic rejuvenating factors and human aging phenotypes.$352,063
R01 · FY2020 · AG · contact PI
Lysophosphatidylcholines and Cognition (L-COG) Study$122,813
R21 · FY2020 · HL · contact PI
Systemic rejuvenating factors and human aging phenotypes.$352,063
R01 · FY2019 · AG · contact PI
Systemic rejuvenating factors and human aging phenotypes.$352,063
R01 · FY2018 · AG · contact PI
Oxidative stress and the pathogenesis of sarcopenia and disability in older women$298,890
R01 · FY2018 · AG · contact PI
Oxidative stress and the pathogenesis of sarcopenia and disability in older women$332,100
R01 · FY2017 · AG · contact PI
Systemic complement and age-related macular degeneration.$472,232
R01 · FY2016 · EY · contact PI
Oxidative stress and the pathogenesis of sarcopenia and disability in older women$332,100
R01 · FY2016 · AG · contact PI
Relationship of candidate circulating proteoforms with aging phenotypes.$210,600
R56 · FY2016 · AG · contact PI
Systemic complement and age-related macular degeneration.$559,312
R01 · FY2015 · EY · contact PI
Klotho and the pathogenesis of cardiovascular disease$358,494
R01 · FY2015 · HL · contact PI
Systemic complement and age-related macular degeneration.$596,377
R01 · FY2014 · EY · contact PI
Klotho and the pathogenesis of cardiovascular disease$356,691
R01 · FY2014 · HL · contact PI
Oxidative stress and the pathogenesis of sarcopenia and disability in older women$232,470
R01 · FY2014 · AG · contact PI
Klotho and the pathogenesis of cardiovascular disease$346,514
R01 · FY2013 · HL · contact PI
Oxidative Stress and Pathogenesis of Sarcopenia and Disability in Older Women$219,685
R01 · FY2013 · AG · contact PI
Klotho and cardiovascular disease in the Honolulu Heart Program$115,668
R21 · FY2013 · HL · contact PI
Klotho and the pathogenesis of cardiovascular disease$420,001
R01 · FY2012 · HL · contact PI
Oxidative stress and the pathogenesis of sarcopenia and disability in older women$232,470
R01 · FY2012 · AG · contact PI
Klotho and cardiovascular disease in the Honolulu Heart Program$121,500
R21 · FY2012 · HL · contact PI
Advanced glycation end products and cardiovascular disease$410,000
R01 · FY2011 · HL · contact PI
Oxidative Stress and the Pathogeneisis of Sarcopenia and Disability in Older Wome$331,132
R01 · FY2011 · AG · contact PI
Advanced glycation end products and cardiovascular disease$410,000
R01 · FY2010 · HL · contact PI
Oxidative Stress and the Pathogeneisis of Sarcopenia and Disability in Older Wome$334,556
R01 · FY2010 · AG · contact PI
Hepcidin and the pathogenesis of anemia in older adults.$294,548
R01 · FY2010 · AG · contact PI
Advanced glycation end products and cardiovascular disease$410,000
R01 · FY2009 · HL · contact PI
Oxidative Stress and the Pathogeneisis of Sarcopenia and Disability in Older Wome$329,743
R01 · FY2009 · AG · contact PI
Hepcidin and the pathogenesis of anemia in older adults.$297,497
R01 · FY2009 · AG · contact PI
Oxidative Stress and the Pathogenesis of Sarcopenia and Disability in Older Women$391,342
R56 · FY2008 · AG · contact PI
Hepcidin and the pathogenesis of anemia in older adults.$297,468
R01 · FY2008 · AG · contact PI
Oxidative stress and the pathogenesis of sarcopenia and*$335,880
R01 · FY2007 · AG · contact PI
Hepcidin and the pathogenesis of anemia in older adults.$319,194
R01 · FY2007 · AG · contact PI
Oxidative stress and the pathogenesis of sarcopenia and*$325,942
R01 · FY2006 · AG · contact PI
BEEF CONSUMPTION TO REDUCE IRON DEFICIENCY AND COGNITIVE FUNCTION IN WOMEN$2,192
M01 · FY2006 · RR · contact PI
Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS$655,412
R01 · FY2005 · AI
Oxidative stress and the pathogenesis of sarcopenia and*$322,568
R01 · FY2005 · AG
Minority Women IDUs in an Inner City HIV Trial$81,750
R03 · FY2005 · NR
Iron Deficiency and Anemia in HIV and HCV-Infected Women$73,473
R01 · FY2005 · DA
Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS$618,234
R01 · FY2004 · AI
Iron Deficiency and Anemia in HIV and HCV-Infected Women$456,651
R01 · FY2004 · DA
Minority Women IDUs in an Inner City HIV Trial$81,750
R03 · FY2004 · NR
Iron Deficiency and Anemia in HIV and HCV-Infected Women$587,460
R01 · FY2003 · DA
Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS$309,055
R01 · FY2003 · AI
Iron Deficiency and Anemia in HIV and HCV-Infected Women$102,448
R01 · FY2003 · DA
Iron Deficiency and Anemia in HIV and HCV-Infected Women$611,773
R01 · FY2002 · DA
ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS$454,108
R01 · FY2002 · AI
VITAMIN A SUPPLEMENTATION FOR HIV INFECTED CHILDREN$391,494
R01 · FY2002 · HD
Iron Deficiency and Anemia in HIV and HCV Infected Women$618,203
R01 · FY2001 · DA
VITAMIN A SUPPLEMENTATION FOR HIV INFECTED CHILDREN$522,514
R01 · FY2001 · HD
MICRONUTRIENTS AND MOTHER TO CHILD TRANSMISSION OF HIV$503,697
R01 · FY2001 · HD
ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS$486,506
R01 · FY2001 · AI
MICRONUTRIENTS AND MOTHER TO CHILD TRANSMISSION OF HIV$65,989
R01 · FY2001 · HD
ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS$53,552
R01 · FY2001 · AI
MICRONUTRIENTS AND MOTHER TO CHILD TRANSMISSION OF HIV$514,746
R01 · FY2000 · HD
ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS$437,410
R01 · FY2000 · AI
VITAMIN A SUPPLEMENTATION FOR HIV INFECTED CHILDREN$412,538
R01 · FY2000 · HD
VITAMIN A SUPPLEMENTATION FOR HIV-INFECTED CHILDREN$100,000
R01 · FY2000 · HD